CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 108 enrolled
Drug / intervention
IL5/IL5R Antagonistsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06239441
NCT06239441N/ACompleted

Assessment and Prediction of the Effectiveness of Mepolizumab Anti-IL-5/IL5R Inhibitors in a Real-world Setting

In Brief

An observational study evaluating IL5/IL5R Antagonists for Severe Asthma. Completed, enrolled 108 participants across 1 site.

Detailed Summary

The goal of this observational study is to assess the response to treatment, in patients 18 years and older diagnosed with severe asthma in whom an IL5/IL5R antagonists was initiated between 2012 and 2020. The main question\[s\] it aims to answer are: * What is the response rate after one year of treatment with IL5/IL5R antagonists. * What is the response and remission rate after one year of treatment with IL5/IL5R antagonists in subjects who fullfilled the original randomized control trials (RCTs) inclusion criteria compared with those who did not.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Asthma
CountriesCanada
CollaboratorsGlaxoSmithKline

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedFeb 2, 2024
Enrollment StartFeb 16, 2021
Primary CompletionJun 13, 2023
Study CompletionNov 29, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 2.4 years ago

Interventions

IL5/IL5R Antagonistsdrug

Treatment with IL5/IL5R antagonists for one year